Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
Phase 1
- Conditions
- Thoracic Solid Malignant Tumor
- Interventions
- Radiation: BNCTDiagnostic Test: ï¼»18Fï¼½FBPA
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Stella Pharma Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT06603987
- Locations
- 🇯🇵
ORIX Kouraibashi Bldg. 8F 3-2-7 Kouraibashi Chuo-ku, Osaka, Japan
A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA
Phase 2
Active, not recruiting
- Conditions
- Unresectable Angiosarcoma
- Interventions
- Radiation: BNCT
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Stella Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT05601232
- Locations
- 🇯🇵
National Cancer Center Hospital, Tokyo, Japan
© Copyright 2025. All Rights Reserved by MedPath